Zai Lab Announces Participation in June Investor Conferences
Zai Lab Limited to participate in investor conferences in June 2023
Positive
Zai Lab Limited announced that members of the senior management team will participate in investor conferences in June 2023
05/25/2023 - 07:30 AM
SHANGHAI, China and CAMBRIDGE, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the company’s senior management team will participate in the following investor conferences in June 2023:
Jefferies Global Healthcare Conference
Goldman Sachs 44th Annual Global Healthcare Conference
About Zai Lab
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, autoimmune disorders, infectious diseases, and neuroscience. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.
For additional information about Zai Lab, including our products, business activities and partnerships, research, and other events or developments, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global .
For more information, please contact:
Investor Relations: Christine Chiou / Lina Zhanglina.zhang@zailaboratory.com
Media : Jennifer Chang / Xiaoyu Chen
Which investor conferences will Zai Lab Limited participate in June 2023?
Zai Lab Limited will participate in Jefferies Global Healthcare Conference and Goldman Sachs 44th Annual Global Healthcare Conference in June 2023.
ZLAB Rankings
#1648 Ranked by Stock Gains
ZLAB Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
China (Mainland)
City
Shanghai
About ZLAB
zai lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. our vision is to address the largest unmet medical needs and transform patients’ lives around the world. we take a unique approach to combine both in-licensed products and internal r&d; to achieve a rich pipeline. we believe our drug candidates can be truly disease modifying and bring significant benefits to patients. the company was founded in 2013 by a group of industry veterans. the founders are known as pioneers in china’s fast advancing biotech industry with a proven track record for successful chinese cfda and us fda filings and approvals. our senior management team introduced fast regulatory approval pathways in china and developed a variety of partnership models with multinational pharmaceutical companies. we endeavor to conduct world class clinical development in china and beyond. zai lab has strong backing from a leading group of healthcare investors. our inve
